The 5-HT6 receptor antagonism approach in Alzheimer's disease

Drugs of the Future

Volumn 39, Issue 2, 2014, Pages 133-140

  Marazziti, D ^a   Rutigliano, G ^a   Catena DelL'Osso, M ^a   Baroni, S ^a   Dell'Osso, L ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

5 HT receptor agonists; 5 Hydroxytryptamine receptors; Alzheimer's disease; Pathophysiology

Indexed keywords

2 (6 FLUORO 1H INDOL 3 YL) N [3 (2,2,3,3,3 PENTAFLUOROPROPOXY)BENZYL]ETHYLAMINE; 3 PHENYLSULFONYL 8 (1 PIPERAZINYL)QUINOLINE; AVN 322; CERLAPIRDINE; PRX 07034; SEROTONIN 6 ANTAGONIST; SEROTONIN 6 RECEPTOR; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; HUMAN; NEUROCHEMISTRY; NEUROMODULATION; PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; SEROTONINERGIC SYSTEM;

EID: 84930537075     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2014.039.02.2103730     Document Type: Review

References (113)

1. Evans, D.A., Funkenstein, H.H., Albert, M.S. et al. Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. JAMA 1989, 262(18): 2551-6.
2. Craig, D., Mirakhur, A., Hart, D.J., McIlroy, S.P., Passmore, A.P. A cross-sectional study of neuropsychiatric symptoms in 435 patients with Alzheimer's disease. Am J Geriatr Psychiatry 2005, 13(6): 460-8.
3. Steffens, D.C., Maytan, M., Helms, M.J., Plassman, B.L. Prevalence and clinical correlates of neuropsychiatric symptoms in dementia. Am J Alzheimers Dis Other Demen 2005, 20(6): 367-73. (Pubitemid 43030926)
4. Lyketsos, C.G., Lee, H.B. Diagnosis and treatment of depression in Alzheimer's disease. A practical update for the clinician. Dement Geriatr Cogn Disord 2004, 17(1-2): 55-64. (Pubitemid 37499969)
5. Friedman, R., Newberger, J. Family care-giving & health care reform. Caring 1993, 12(9): 44-7.
6. Harwood, D.G., Barker, W.W., Ownby, R.L., Duara, R. Relationship of behavioral and psychological symptoms to cognitive impairment and functional status in Alzheimer's disease. Int J Geriatr Psychiatry 2000, 15(5): 393-400. (Pubitemid 30325790)
7. Ropacki, S.A., Jeste, D.V. Epidemiology of and risk factors for psychosis of Alzheimer's disease: A review of 55 studies published from 1990 to 2003. Am J Psychiatry 2005, 162(11): 2022-30. (Pubitemid 41598255)
8. Aarsland, D., Cummings, J.L., Yenner, G., Miller, B. Relationship of aggressive behavior to other neuropsychiatric symptoms in patients with Alzheimer's disease. Am J Psychiatry 1996, 153(2): 243-7. (Pubitemid 26038967)
9. Gilley, D.W., Wilson, R.S., Beckett, L.A., Evans, D.A. Psychotic symptoms and physically aggressive behavior in Alzheimer's disease. J Am Geriatr Soc 1997, 45(9): 1074-9. (Pubitemid 27377553)
10. Kotrla, K.J., Chacko, R.C., Harper, R.G., Doody, R. Clinical variables associated with psychosis in Alzheimer's disease. Am J Psychiatry 1995, 152(9): 1377-9.
11. Francis, P.T., Ramirez, M.J., Lai, M.K. Neurochemical basis for symptomatic treatment of Alzheimer's disease. Neuropharmacology 2010, 59(4-5): 221-9.
12. Hardy, J. The amyloid hypothesis for Alzheimer's disease: A critical reappraisal. J Neurochem 2009, 110(4): 1129-34.
13. Branchek, T.A., Blackburn, T.P. 5-ht6 receptors as emerging targets for drug discovery. Annu Rev Pharmacol Toxicol 2000, 40: 319-34. (Pubitemid 30340685)
14. Codony, X., Vela, J.M., Ramirez, M.J. 5-HT(6) receptor and cognition. Curr Opin Pharmacol 2011, 11(1): 94-100.
15. Marazziti, D., Baroni, S., Catena Dell'Osso, M., Bordi, F., Borsini, F. Serotonin receptors of type 6 (5-HT6): What can we expect from them? Curr Med Chem 2011, 18(18): 2783-90.
16. Ramirez, M.J. 5-HT6 receptors and Alzheimer's disease. Alzheimers Res Ther 2013, 5(2): 15.
17. Clark, L., Roiser, J.P., Cools, R., Rubinsztein, D.C., Sahakian, B.J., Robbins, T.W. Stop signal response inhibition is not modulated by tryptophan depletion or the serotonin transporter polymorphism in healthy volunteers: Implications for the 5-HT theory of impulsivity. Psychopharmacology (Berl) 2005, 182(4): 570-8. (Pubitemid 41464639)
18. Nordquist, N., Oreland, L. Serotonin, genetic variability, behaviour, and psychiatric disorders-A review. Ups J Med Sci 2010, 115(1): 2-10.
19. Zweig, R.M., Ross, C.A., Hedreen, J.C. et al. Neuropathology of aminergic nuclei in Alzheimer's disease. Prog Clin Biol Res 1989, 317: 353-65.
20. Chen, C.P., Eastwood, S.L., Hope, T., McDonald, B., Francis, P.T., Esiri, M.M. Immunocytochemical study of the dorsal and median raphe nuclei in patients with Alzheimer's disease prospectively assessed for behavioural changes. Neuropathol Appl Neurobiol 2000, 26(4): 347-55. (Pubitemid 30609430)
21. Curcio, C.A., Kemper, T. Nucleus raphe dorsalis in dementia of the Alzheimer type: Neurofibrillary changes and neuronal packing density. J Neuropathol Exp Neurol 1984, 43(4): 359-68. (Pubitemid 14089416)
22. Lorke, D.E., Lu, G., Cho, E., Yew, D.T. Serotonin 5-HT2A and 5-HT6 receptors in the prefrontal cortex of Alzheimer and normal aging patients. BMC Neurosci 2006, 7: 36.
23. Gottfries, C.G. Disturbance of the 5-hydroxytryptamine metabolism in brains from patients with Alzheimer's dementia. J Neural Transm Suppl 1990, 30: 33-43.
24. Nazarali, A.J., Reynolds, G.P. Monoamine neurotransmitters and their metabolites in brain regions in Alzheimer's disease: A postmortem study. Cell Mol Neurobiol 1992, 12(6): 581-7.
25. Garcia-Alloza, M., Hirst, W.D., Chen, C.P., Lasheras, B., Francis, P.T., Ramirez, M.J. Differential involvement of 5-HT(1B/1D) and 5-HT6 receptors in cognitive and non-cognitive symptoms in Alzheimer's disease. Neuropsychopharmacology 2004, 29(2): 410-6. (Pubitemid 38175158)
26. Garcia-Alloza, M., Gil-Bea, F.J., Diez-Ariza, M., Chen, C.P., Francis, P.T., Lasheras, B., Ramirez, M.J. Cholinergic-serotonergic imbalance contributes to cognitive and behavioral symptoms in Alzheimer's disease. Neuropsychologia 2005, 43(3): 442-9. (Pubitemid 40222131)
27. Palmer, A.M., Francis, P.T., Benton, J.S. et al. Presynaptic serotonergic dysfunction in patients with Alzheimer's disease. J Neurochem 1987, 48(1): 8-15. (Pubitemid 17031359)
28. Holmes, C., Arranz, M.J., Powell, J.F., Collier, D.A., Lovestone, S. 5-HT2A and 5-HT2C receptor polymorphisms and psychopathology in late onset Alzheimer's disease. Hum Mol Genet 1998, 7(9): 1507-9. (Pubitemid 28429933)
29. Assal, F., Alarcon, M., Solomon, E.C., Masterman, D., Geschwind, D.H., Cummings, J.L. Association of the serotonin transporter and receptor gene polymorphisms in neuropsychiatric symptoms in Alzheimer disease. Arch Neurol 2004, 61(8): 1249-53. (Pubitemid 39062679)
30. Holmes, C., Arranz, M., Collier, D., Powell, J., Lovestone, S. Depression in Alzheimer's disease: The effect of serotonin receptor gene variation. Am J Med Genet B Neuropsychiatr Genet 2003, 119B(1): 40-3. (Pubitemid 37064051)
31. Monsma, F.J., Jr., Shen, Y., Ward, R.P., Hamblin, M.W., Sibley, D.R. Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol Pharmacol 1993, 43(3): 320-7. (Pubitemid 23081986)
32. Roth, B.L., Craigo, S.C., Choudhary, M.S. et al. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 1994, 268(3): 1403-10. (Pubitemid 24100360)
33. Kohen, R., Metcalf, M.A., Khan, N. et al. Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor. J Neurochem 1996, 66(1): 47-56. (Pubitemid 26010763)
34. Riemer, C., Borroni, E., Levet-Trafit, B., Martin, J.R., Poli, S., Porter, R.H., Bos, M. Influence of the 5-HT6 receptor on acetylcholine release in the cortex: Pharmacological characterization of 4-(2-bromo-6-pyrrolidin-1- ylpyridine-4-sulfonyl)phenylamine, a potent and selective 5-HT6 receptor antagonist. J Med Chem 2003, 46(7): 1273-6. (Pubitemid 36428233)
35. Setola, V., Roth, B.L. Why mice are neither miniature humans nor small rats: A cautionary tale involving 5-hydroxytryptamine-6 serotonin receptor species variants. Mol Pharmacol 2003, 64(6): 1277-8. (Pubitemid 37532216)
36. Hirst, W.D., Abrahamsen, B., Blaney, F.E., Calver, A.R., Aloj, L., Price, G.W., Medhurst, A.D. Differences in the central nervous system distribution and pharmacology of the mouse 5-hydroxytryptamine-6 receptor compared with rat and human receptors investigated by radioligand binding, site-directed mutagenesis, and molecular modeling. Mol Pharmacol 2003, 64(6): 1295-308. (Pubitemid 37532219)
37. Bonasera, S.J., Chu, H.M., Brennan, T.J., Tecott, L.H. A null mutation of the serotonin 6 receptor alters acute responses to ethanol. Neuropsychopharmacology 2006, 31(8): 1801-13. (Pubitemid 44106712)
38. Bibancos, T., Jardim, D.L., Aneas, I., Chiavegatto, S. Social isolation and expression of serotonergic neurotransmission-related genes in several brain areas of male mice. Genes Brain Behav 2007, 6(6): 529-39. (Pubitemid 47246219)
39. Olsen, M.A., Nawoschik, S.P., Schurman, B.R., Schmitt, H.L., Burno, M., Smith, D.L., Schechter, L.E. Identification of a human 5-HT6 receptor variant produced by alternative splicing. Brain Res Mol Brain Res 1999, 64(2): 255-63. (Pubitemid 29052476)
40. Ruat, M., Traiffort, E., Arrang, J.M., Tardivel-Lacombe, J., Diaz, J., Leurs, R., Schwartz, J.C. A novel rat serotonin (5-HT6) receptor: Molecular cloning, localization and stimulation of cAMP accumulation. Biochem Biophys Res Commun 1993, 193(1): 268-76. (Pubitemid 23199942)
41. Kohen, R., Fashingbauer, L.A., Heidmann, D.E., Guthrie, C.R., Hamblin, M.W. Cloning of the mouse 5-HT6 serotonin receptor and mutagenesis studies of the third cytoplasmic loop. Brain Res Mol Brain Res 2001, 90(2): 110-7. (Pubitemid 32537632)
42. Gerard, C., el Mestikawy, S., Lebrand, C. et al. Quantitative RT-PCR distribution of serotonin 5-HT6 receptor mRNA in the central nervous system of control or 5,7-dihydroxytryptamine-treated rats. Synapse 1996, 23(3): 164-73. (Pubitemid 26230563)
43. Ward, R.P., Hamblin, M.W., Lachowicz, J.E., Hoffman, B.J., Sibley, D.R., Dorsa, D.M. Localization of serotonin subtype 6 receptor messenger RNA in the rat brain by in situ hybridization histochemistry. Neuroscience 1995, 64(4): 1105-11.
44. Ward, R.P., Dorsa, D.M. Colocalization of serotonin receptor subtypes 5-HT2A, 5-HT2C, and 5-HT6 with neuropeptides in rat striatum. J Comp Neurol 1996, 370(3): 405-14. (Pubitemid 26235237)
45. Gerard, C., Martres, M.P., Lefevre, K. et al. Immuno-localization of serotonin 5-HT6 receptor-like material in the rat central nervous system. Brain Res 1997, 746(1-2): 207-19. (Pubitemid 27060349)
46. Hamon, M., Doucet, E., Lefevre, K. et al. Antibodies and antisense oligonucleotide for probing the distribution and putative functions of central 5-HT6 receptors. Neuropsychopharmacology 1999, 21(2, Suppl.): 68S-76S. (Pubitemid 29396473)
47. Hirst, W.D., Minton, J.A., Bromidge, S.M. et al. Characterization of [(125)I]SB-258585 binding to human recombinant and native 5-HT(6) receptors in rat, pig and human brain tissue. Br J Pharmacol 2000, 130(7): 1597-605. (Pubitemid 30611937)
48. Roberts, J.C., Reavill, C., East, S.Z., Harrison, P.J., Patel, S., Routledge, C., Leslie, R.A. The distribution of 5-HT(6) receptors in rat brain: An autoradiographic binding study using the radiolabelled 5-HT(6) receptor antagonist [(125)I]SB-258585. Brain Res 2002, 934(1): 49-57. (Pubitemid 34286567)
49. Yoshioka, M., Matsumoto, M., Togashi, H., Mori, K. Central distribution and function of 5-ht6 receptor subtype in the rat brain. Ann N Y Acad Sci 1998, 861: 244. (Pubitemid 29047727)
50. Woolley, M.L., Marsden, C.A., Fone, K.C. 5-ht6 receptors. Curr Drug Targets CNS Neurol Disord 2004, 3(1): 59-79.
51. Bonsi, P., Cuomo, D., Ding, J. et al. Endogenous serotonin excites striatal cholinergic interneurons via the activation of 5-HT 2C, 5-HT6, and 5-HT7 serotonin receptors: Implications for extrapyramidal side effects of serotonin reuptake inhibitors. Neuropsychopharmacology 2007, 32(8): 1840-54. (Pubitemid 47076377)
52. Riccio, O., Potter, G., Walzer, C. et al. Excess of serotonin affects embryonic interneuron migration through activation of the serotonin receptor 6. Mol Psychiatry 2009, 14(3): 280-90.
53. Jackson, Z.E., Stringer, B.M., Foster, G.A. Identification of 5-HT receptor sub-types in a homogeneous population of presumptive serotoninergic neurones. Neuropharmacology 1997, 36(4-5): 543-8. (Pubitemid 27272099)
54. Marazziti, D., Baroni, S., Pirone, A. et al. Distribution of serotonin receptor of type 6 (5-HT(6)) in human brain post-mortem. A pharmacology, autoradiography and immunohistochemistry study. Neurochem Res 2012, 37(5): 920-7.
55. Marazziti, D., Baroni, S., Pirone, A. et al. Serotonin receptor of type 6 (5-HT6) in human prefrontal cortex and hippocampus post-mortem: An immunohistochemical and immunofluorescence study. Neurochem Int 2013, 62(2): 182-8.
56. Marcos, B., Cabero, M., Solas, M., Aisa, B., Ramirez, M.J. Signalling pathways associated with 5-HT6 receptors: Relevance for cognitive effects. Int J Neuropsychopharmacol 2010, 13(6): 775-84.
57. Schechter, L.E., Lin, Q., Smith, D.L. et al. Neuropharmacological profile of novel and selective 5-HT6 receptor agonists: WAY-181187 and WAY-208466. Neuropsychopharmacology 2008, 33(6): 1323-35. (Pubitemid 351521711)
58. Marcos, B., Aisa, B., Ramirez, M.J. Functional interaction between 5-HT(6) receptors and hypothalamic-pituitary-adrenal axis: Cognitive implications. Neuropharmacology 2008, 54(4): 708-14.
59. Marcos, B., Gil-Bea, F.J., Hirst, W.D., Garcia-Alloza, M., Ramirez, M.J. Lack of localization of 5-HT6 receptors on cholinergic neurons: Implication of multiple neurotransmitter systems in 5-HT6 receptor-mediated acetylcholine release. Eur J Neurosci 2006, 24(5): 1299-306. (Pubitemid 44401652)
60. West, P.J., Marcy, V.R., Marino, M.J., Schaffhauser, H. Activation of the 5-HT(6) receptor attenuates long-term potentiation and facilitates GABAergic neurotransmission in rat hippocampus. Neuroscience 2009, 164(2): 692-701.
61. Lacroix, L.P., Dawson, L.A., Hagan, J.J., Heidbreder, C.A. 5-HT6 receptor antagonist SB-271046 enhances extracellular levels of monoamines in the rat medial prefrontal cortex. Synapse 2004, 51(2): 158-64. (Pubitemid 38018798)
62. Dawson, L.A., Nguyen, H.Q., Li, P. In vivo effects of the 5-HT(6) antagonist SB-271046 on striatal and frontal cortex extracellular concentrations of noradrenaline, dopamine, 5-HT, glutamate and aspartate. Br J Pharmacol 2000, 130(1): 23-6. (Pubitemid 30248421)
63. Dawson, L.A., Nguyen, H.Q., Li, P. The 5-HT(6) receptor antagonist SB-271046 selectively enhances excitatory neurotransmission in the rat frontal cortex and hippocampus. Neuropsychopharmacology 2001, 25(5): 662-8. (Pubitemid 32995948)
64. Frantz, K.J., Hansson, K.J., Stouffer, D.G., Parsons, L.H. 5-HT(6) receptor antagonism potentiates the behavioral and neurochemical effects of amphetamine but not cocaine. Neuropharmacology 2002, 42(2): 170-80. (Pubitemid 34137020)
65. Doleviczenyi, Z., Vizi, E.S., Gacsalyi, I. et al. 5-HT6/7 receptor antagonists facilitate dopamine release in the cochlea via a GABAergic disinhibitory mechanism. Neurochem Res 2008, 33(11): 2364-72.
66. Valentini, V., Frau, R., Bordi, F., Borsini, F., Di Chiara, G. A microdialysis study of ST1936, a novel 5HT6 receptor agonist. Neuropharmacology 2011, 60(4): 602-8.
67. Minabe, Y., Shirayama, Y., Hashimoto, K., Routledge, C., Hagan, J.J., Ashby, C.R. Jr. Effect of the acute and chronic administration of the selective 5-HT6 receptor antagonist SB-271046 on the activity of midbrain dopamine neurons in rats: An in vivo electrophysiological study. Synapse 2004, 52(1): 20-8. (Pubitemid 38316267)
68. Boess, F.G., Monsma, F.J. Jr., Sleight, A.J. Identification of residues in transmembrane regions III and VI that contribute to the ligand binding site of the serotonin 5-HT6 receptor. J Neurochem 1998, 71(5): 2169-77. (Pubitemid 28491575)
69. Bromidge, S.M., Griffith, K., Heightman, T.D. et al. Novel (4-piperazin-1-ylquinolin-6-yl) arylsulfonamides with high affinity and selectivity for the 5-HT(6) receptor. Bioorg Med Chem Lett 2001, 11(21): 2843-6.
70. Kang, H., Lee, W.K., Choi, Y.H., Vukoti, K.M., Bang, W.G., Yu, Y.G. Molecular analysis of the interaction between the intracellular loops of the human serotonin receptor type 6 (5-HT6) and the alpha subunit of GS protein. Biochem Biophys Res Commun 2005, 329(2): 684-92. (Pubitemid 40311798)
71. Romero, G., Sanchez, E., Pujol, M. et al. Efficacy of selective 5-HT6 receptor ligands determined by monitoring 5-HT6 receptor-mediated cAMP signaling pathways. Br J Pharmacol 2006, 148(8): 1133-43. (Pubitemid 44223019)
72. Schoeffter, P., Waeber, C. 5-Hydroxytryptamine receptors with a 5-HT6 receptor-like profile stimulating adenylyl cyclase activity in pig caudate membranes. Naunyn Schmiedebergs Arch Pharmacol 1994, 350(4): 356-60.
73. Yun, H.M., Baik, J.H., Kang, I., Jin, C., Rhim, H. Physical interaction of Jab1 with human serotonin 6 G-protein-coupled receptor and their possible roles in cell survival. J Biol Chem 2010, 285(13): 10016-29.
74. Bromidge, S.M., Clarke, S.E., Gager, T. et al. Phenyl benzenesulfonamides are novel and selective 5-HT6 antagonists: Identification of N-(2,5-dibromo-3-fluorophenyl)-4-methoxy-3-piperazin-1-ylbenzenesulfonamide (SB-357134). Bioorg Med Chem Lett 2001, 11(1): 55-8. (Pubitemid 32006123)
75. Alcalde, E., Mesquida, N., Lopez-Perez, S. et al. Indene-based frameworks targeting the 5-HT6 serotonin receptor: ring constraint in indenylsulfonamides using cyclic amines and structurally abbreviated counterparts. Bioorg Med Chem 2009, 17(20): 7387-97.
76. Baker, L.P., Nielsen, M.D., Impey, S. et al. Stimulation of type 1 and type 8 Ca2+/calmodulin-sensitive adenylyl cyclases by the Gs-coupled 5-hydroxytryptamine subtype 5-HT7A receptor. J Biol Chem 1998, 273(28): 17469-76. (Pubitemid 28355078)
77. Dupuis, D.S., Mannoury la Cour, C., Chaput, C., Verriele, L., Lavielle, G., Millan, M.J. Actions of novel agonists, antagonists and antipsychotic agents at recombinant rat 5-HT6 receptors: A comparative study of coupling to G alpha s. Eur J Pharmacol 2008, 588(2-3): 170-7.
78. Bymaster, F.P., Falcone, J.F., Bauzon, D., Kennedy, J.S., Schenck, K., DeLapp, N.W., Cohen, M.L. Potent antagonism of 5-HT(3) and 5-HT(6) receptors by olanzapine. Eur J Pharmacol 2001, 430(2-3): 341-9. (Pubitemid 33050060)
79. Yun, H.M., Kim, S., Kim, H.J. et al. The novel cellular mechanism of human 5-HT6 receptor through an interaction with Fyn. J Biol Chem 2007, 282(8): 5496-505. (Pubitemid 47093777)
80. Purohit, A., Herrick-Davis, K., Teitler, M. Creation, expression, and characterization of a constitutively active mutant of the human serotonin 5-HT6 receptor. Synapse 2003, 47(3): 218-24. (Pubitemid 36056835)
81. Sleight, A.J., Boess, F.G., Bos, M., Levet-Trafit, B., Riemer, C., Bourson, A. Characterization of Ro 04-6790 and Ro 63-0563: Potent and selective antagonists at human and rat 5-HT6 receptors. Br J Pharmacol 1998, 124(3): 556-62. (Pubitemid 28254513)
82. Bos, M., Sleight, A.J., Godel, T., Martin, J.R., Riemer, C., Stadler, H. 5-HT(6) receptor antagonists: Lead optimisation and biological evaluation of N-aryl and N-heteroaryl 4-amino-benzene sulfonamides. Eur J Med Chem 2001, 36(2): 165-78. (Pubitemid 32304518)
83. Ahmed, M., Briggs, M.A., Bromidge, S.M. et al. Bicyclic heteroarylpiperazines as selective brain penetrant 5-HT6 receptor antagonists. Bioorg Med Chem Lett 2005, 15(21): 4867-71. (Pubitemid 41354824)
84. Trani, G., Baddeley, S.M., Briggs, M.A. et al. Tricyclic azepine derivatives as selective brain penetrant 5-HT6 receptor antagonists. Bioorg Med Chem Lett 2008, 18(20): 5698-700.
85. 6 receptor antagonist SB-3999885 in animal models of anxiety and depression. Neuropharmacology 2007, 52(5): 1274-83.
86. Bromidge, S.M., Dabbs, S., Davies, D.T. et al. Model studies on a synthetically facile series of N-substituted phenyl-N′-pyridin-3-yl ureas leading to 1-(3-pyridylcarbamoyl) indolines that are potent and selective 5-HT(2C/2B) receptor antagonists. Bioorg Med Chem 1999, 7(12): 2767-73. (Pubitemid 30105850)
87. 6 antagonist, PRX-07034, enhances memory and reduces food intake in a neurodevelopmental model of schizophrenia. J Psychopharmacol 2007, 21: A57.
88. Hugerth, A., Brisander, M., Wrange, U. et al. Physical characterization of anhydrous and hydrous forms of the hydrochloride salt of BVT.5182 a novel 5-HT(6) receptor antagonist. Drug Dev Ind Pharm 2006, 32(2): 185-96.
89. Suter, L., Haiker, M., De Vera, M.C., Albertini, S. Effect of two 5-HT6 receptor antagonists on the rat liver: A molecular approach. Pharmacogenomics J 2003, 3(6): 320-34. (Pubitemid 38072170)
90. Glennon, R.A., Lee, M., Rangisetty, J.B. et al. 2-Substituted tryptamines: Agents with selectivity for 5-HT(6) serotonin receptors. J Med Chem 2000, 43(5): 1011-8. (Pubitemid 30152305)
91. th Annu Meet Soc Neurosci (Oct 23-27, San Diego) 2004, Abst 394.11.
92. Cole, D.C., Stock, J.R., Lennox, W.J. et al. Discovery of N1-(6-chloroimidazo[2,1-b][1,3]thiazole-5-sulfonyl)tryptamine as a potent, selective, and orally active 5-HT(6) receptor agonist. J Med Chem 2007, 50(23): 5535-8. (Pubitemid 350106003)
93. Alcalde, E., Mesquida, N., Frigola, J., Lopez-Perez, S., Merce, R. Indene-based scaffolds. Design and synthesis of novel serotonin 5-HT6 receptor ligands. Org Biomol Chem 2008, 6(20): 3795-810.
94. Cole, D.C., Lennox, W.J., Lombardi, S. et al. Discovery of 5-arylsulfonamido-3-(pyrrolidin-2-ylmethyl)-1H-indole derivatives as potent, selective 5-HT6 receptor agonists and antagonists. J Med Chem 2005, 48(2): 353-6. (Pubitemid 40139779)
95. Tsai, Y., Dukat, M., Slassi, A. et al. N1-(Benzenesulfonyl)tryptamines as novel 5-HT6 antagonists. Bioorg Med Chem Lett 2000, 10(20): 2295-9.
96. Russell, M.G., Baker, R.J., Barden, L. et al. N-Arylsulfonylindole derivatives as serotonin 5-HT(6) receptor ligands. J Med Chem 2001, 44(23): 3881-95. (Pubitemid 33051478)
97. Glennon, R.A. Higher-end serotonin receptors: 5-HT(5), 5-HT(6), and 5-HT(7). J Med Chem 2003, 46(14): 2795-812.
98. Holenz, J., Merce, R., Diaz, J.L. et al. Medicinal chemistry driven approaches toward novel and selective serotonin 5-HT6 receptor ligands. J Med Chem 2005, 48(6): 1781-95. (Pubitemid 40396311)
99. Holenz, J., Pauwels, P.J., Diaz, J.L., Merce, R., Codony, X., Buschmann, H. Medicinal chemistry strategies to 5-HT(6) receptor ligands as potential cognitive enhancers and antiobesity agents. Drug Discov Today 2006, 11(7-8): 283-99.
100. .Kim, H.J., Doddareddy, M.R., Choo, H., Cho, Y.S., No, K.T., Park, W.K., Pae, A.N. New serotonin 5-HT(6) ligands from common feature pharmacophore hypotheses. J Chem Inf Model 2008, 48(1): 197-206. (Pubitemid 351271065)
101. Ivachtchenko, A.V., Frolov, E.B., Mitkin, O.D., Kysil, V.M., Khvat, A.V., Okun, I.M., Tkachenko, S.E. Synthesis and biological evaluation of novel gamma-carboline analogues of dimebon as potent 5-HT6 receptor antagonists. Bioorg Med Chem Lett 2009, 19(12): 3183-7.
102. Lane, H.Y., Liu, Y.C., Huang, C.L. et al. Prefrontal executive function and D1, D3, 5-HT2A and 5-HT6 receptor gene variations in healthy adults. J Psychiatry Neurosci 2008, 33(1): 47-53.
103. Thome, J., Retz, W., Baader, M. et al. Association analysis of HTR6 and HTR2A polymorphisms in sporadic Alzheimer's disease. J Neural Transm 2001, 108(10): 1175-80. (Pubitemid 33022767)
104. Meneses, A., Perez-Garcia, G., Ponce-Lopez, T., Castillo, C. 5-HT6 receptor memory and amnesia: Behavioral pharmacology - learning and memory processes. Int Rev Neurobiol 2011, 96: 27-47.
105. Fone, K.C. An update on the role of the 5-hydroxytryptamine6 receptor in cognitive function. Neuropharmacology 2008, 55(6): 1015-22.
106. Kendall, I., Slotten, H.A., Codony, X., Burgueno, J., Pauwels, P.J., Vela, J.M., Fone, K.C. E-6801, a 5-HT6 receptor agonist, improves recognition memory by combined modulation of cholinergic and glutamatergic neurotransmission in the rat. Psychopharmacology (Berl) 2011, 213(2-3): 413-30.
107. de Foubert, G., O'Neill, M.J., Zetterstrom, T.S. Acute onset by 5-HT(6)-receptor activation on rat brain brain-derived neurotrophic factor and activity-regulated cytoskeletal-associated protein mRNA expression. Neuroscience 2007, 147(3): 778-85. (Pubitemid 46990655)
108. Burnham, K.E., Baxter, M.G., Bainton, J., Southam, E., Dawson, L.A., Sharp, T., Banneman, D.M. The 5-HT6 receptor agonist WAY181187 enhances extradimensional set-shifting in the rat. Brit J Pharmacol 2007, 5: 27P.
109. Upton, N., Chuang, T.T., Hunter, A.J., Virley, D.J. 5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer's disease. Neurotherapeutics 2008, 5(3): 458-69. (Pubitemid 351952494)
110. Doody, R.S., Gavrilova, S.I., Sano, M. et al. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: A randomised, double-blind, placebo-controlled study. Lancet 2008, 372(9634): 207-15. (Pubitemid 351978110)
111. Jones, R.W. Dimebon disappointment. Alzheimers Res Ther 2010, 2(5): 25.
112. 6 serotonin receptor-coupled adenylyl cyclase in stably transfected HEK-293 cells. J Serotonin Res 1995, 2: 101-16.
113. Ivachtchenko, A.V., Ivanenkov, Y.A., Tkachenko, S.E. 5-Hydroxytryptamine subtype 6 receptor modulators: A patent survey. Expert Opin Ther Pat 2010, 20(9): 1171-96.